XTL, Biostapro antibody deal

XTL Biopharmaceuticals (LSE:XTL) licensed from Biostapro (Uppsala, Sweden) two cell surface targets expressed in staphylococcal bacteria S. aureus and S. epidermidis. The companies will develop human ...